{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:21:00Z","timestamp":1788232860990,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204262"],"award-info":[{"award-number":["82204262"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.biopha.2025.118583","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T23:00:45Z","timestamp":1758582045000},"page":"118583","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Comparative evaluation of bispecific antibody formats targeting PD-1 and LAG-3 for dual checkpoint blockade in cancer immunotherapy"],"prefix":"10.1016","volume":"192","author":[{"given":"Jie","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinnan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyihua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaowei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuechen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiannan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxia","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8307-6478","authenticated-orcid":false,"given":"Longlong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.biopha.2025.118583_bib1","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41590-019-0512-0","article-title":"Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups[J]","volume":"20","author":"Andrews","year":"2019","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118583_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer Immunotherapy[J]","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.biopha.2025.118583_bib3","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41419-025-07471-w","article-title":"High baseline levels of PD-L1 reduce the heterogeneity of immune checkpoint signature and sensitize anti-PD1 therapy in lung and colorectal cancers","volume":"16","author":"Fan","year":"2025","journal-title":"J. ]. Cell Death Dis."},{"issue":"3","key":"10.1016\/j.biopha.2025.118583_bib4","first-page":"182","article-title":"Effect of pembrolizumab on t lymphocyte subsets in patients with advanced \u07edNon-small cell lung cancer and its therapeutic Effect][J]","volume":"24","author":"Wang","year":"2021","journal-title":"Zhongguo Fei Ai Za Zhi"},{"issue":"12","key":"10.1016\/j.biopha.2025.118583_bib5","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/s41423-024-01227-w","article-title":"No more LAGging behind PD-1: uncovering the unique role of LAG-3 in T-cell exhaustion[J]","volume":"21","author":"Jo","year":"2024","journal-title":"Cell Mol. Immunol."},{"issue":"16","key":"10.1016\/j.biopha.2025.118583_bib6","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1016\/j.cell.2024.07.018","article-title":"LAG-3 sustains TOX expression and regulates the CD94\/NKG2-Qa-1b axis to govern exhausted CD8 t cell NK receptor expression and cytotoxicity[J]","volume":"187","author":"Ngiow","year":"2024","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.biopha.2025.118583_bib7","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/imr.12519","article-title":"LAG3 (CD223) as a cancer immunotherapy target[J]","volume":"276","author":"Andrews","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.biopha.2025.118583_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.951817","article-title":"PD-1\/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma[J]","volume":"13","author":"Zhong","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118583_bib9","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jaad.2019.03.012","article-title":"Expression of lymphocyte-activating gene 3 and T-cell immunoreceptor with immunoglobulin and ITIM domains in cutaneous melanoma and their correlation with programmed cell death 1 expression in tumor-infiltrating lymphocytes[J]","volume":"81","author":"Lee","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.biopha.2025.118583_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.818411","article-title":"Expression profiles and prognostic value of multiple inhibitory checkpoints in head and neck Lymphoepithelioma-Like Carcinoma[J]","volume":"13","author":"Zou","year":"2022","journal-title":"Front. Immunol."},{"issue":"17","key":"10.1016\/j.biopha.2025.118583_bib11","doi-asserted-by":"crossref","first-page":"7875","DOI":"10.1073\/pnas.1003345107","article-title":"Tumor-infiltrating NY-ESO-1-specific CD8+ t cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer[J]","volume":"107","author":"Matsuzaki","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2025.118583_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102172","article-title":"Avelumab and cetuximab as a therapeutic combination: an overview of scientific rationale and current clinical trials in cancer[J]","volume":"97","author":"Bourhis","year":"2021","journal-title":"Cancer Treat. Rev."},{"issue":"4","key":"10.1016\/j.biopha.2025.118583_bib13","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41591-024-02877-z","article-title":"Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal\/gastroesophageal junction cancer: a phase ib trial and ctDNA analyses[J]","volume":"30","author":"Kelly","year":"2024","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.biopha.2025.118583_bib14","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13045-024-01651-5","article-title":"Dual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab in advanced solid tumors: the first-in-human phase Ia\/Ib study[J]","volume":"17","author":"Mao","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118583_bib15","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s11912-023-01406-4","article-title":"The latest option: nivolumab and relatlimab in advanced Melanoma[J]","volume":"25","author":"Albrecht","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.biopha.2025.118583_bib16","doi-asserted-by":"crossref","unstructured":"H.A. Tawbi, D. Schadendorf, E.J. Lipson, P.A. Ascierto, L. Matamala, E.C. Guti\u00e9rrez, P. Rutkowski, H.J. Gogas, C.D. Lao, J.J.D. Menezes, S. Dalle, A. Arance, J.-J. Grob, S. Srivastava, M. Abaskharoun, M. Hamilton, S. Keidel, K.L. Simonsen, A.M. Sobiesk, B. Li, F.S. Hodi, G.V. Long, 2022, Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma[J]. 2022, 386 (1):24-34.","DOI":"10.1056\/NEJMoa2109970"},{"issue":"11","key":"10.1016\/j.biopha.2025.118583_bib17","first-page":"970","article-title":"PD-1 and LAG-3 dual blockade: emerging mechanisms and potential therapeutic prospects in cancer[J]","volume":"21","author":"Qiu","year":"2024","journal-title":"Cancer Biol. Med"},{"issue":"8","key":"10.1016\/j.biopha.2025.118583_bib18","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline[J]","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2 Pt A","key":"10.1016\/j.biopha.2025.118583_bib19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molimm.2015.01.003","article-title":"Alternative molecular formats and therapeutic applications for bispecific antibodies[J]","volume":"67","author":"Spiess","year":"2015","journal-title":"Mol. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118583_bib20","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4161\/mabs.4.2.19000","article-title":"Dual targeting strategies with bispecific antibodies[J]","volume":"4","author":"Kontermann","year":"2012","journal-title":"mAbs"},{"issue":"45","key":"10.1016\/j.biopha.2025.118583_bib21","article-title":"Broad-Spectrum engineered multivalent nanobodies against SARS-CoV-1\/2[J]","volume":"11","author":"Wang","year":"2024","journal-title":"Adv. Sci. (Weinh. )"},{"issue":"6","key":"10.1016\/j.biopha.2025.118583_bib22","article-title":"Development of a Macrophage-Based ADCC Assay[J]","volume":"9","author":"Uccellini","year":"2021","journal-title":"Vaccin. (Basel)"},{"issue":"9","key":"10.1016\/j.biopha.2025.118583_bib23","article-title":"Incorporating the cluster a and V1V2 targets into a minimal structural unit of the HIV-1 envelope to elicit a Cross-Clade response with potent Fc-Effector Functions[J]","volume":"9","author":"Sherburn","year":"2021","journal-title":"Vaccin. (Basel)"},{"key":"10.1016\/j.biopha.2025.118583_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.scr.2022.102935","article-title":"Generation of CD16A gene knockout human embryonic stem cell line using CRISPR\/Cas9[J]","volume":"64","author":"Wu","year":"2022","journal-title":"Stem Cell Res."},{"issue":"1","key":"10.1016\/j.biopha.2025.118583_bib25","doi-asserted-by":"crossref","first-page":"7938","DOI":"10.1038\/s41598-024-58541-6","article-title":"Distinct CD16a features on human NK cells observed by flow cytometry correlate with increased ADCC[J]","volume":"14","author":"Benavente","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2025.118583_bib26","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.bbrc.2021.02.057","article-title":"Identification of a novel protective human monoclonal antibody, LXY8, that targets the key neutralizing epitopes of staphylococcal enterotoxin B[J]","volume":"549","author":"Hu","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"577","key":"10.1016\/j.biopha.2025.118583_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aar3641","article-title":"Cooperation between t cell receptor and Toll-like receptor 5 signaling for CD4(+) t cell activation[J]","volume":"12","author":"Rodr\u00edguez-Jorge","year":"2019","journal-title":"Sci. Signal"},{"issue":"4","key":"10.1016\/j.biopha.2025.118583_bib28","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of t cell co-stimulation and co-inhibition[J]","volume":"13","author":"Chen","year":"2013","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118583_bib29","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/imcb.12636","article-title":"T-cell activation-induced marker assays in health and disease[J]","volume":"101","author":"Poloni","year":"2023","journal-title":"Immunol. Cell Biol."},{"issue":"10","key":"10.1016\/j.biopha.2025.118583_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102645","article-title":"Low-dose Interleukin-2: biology and therapeutic prospects in rheumatoid arthritis[J]","volume":"19","author":"Wu","year":"2020","journal-title":"Autoimmun. Rev."},{"issue":"25","key":"10.1016\/j.biopha.2025.118583_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aat1482","article-title":"Revisiting IL-2: biology and therapeutic prospects[J]","volume":"3","author":"Abbas","year":"2018","journal-title":"Sci. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118583_bib32","first-page":"111","article-title":"Expression of PD-1 and PD-L1 in the peripheral blood of advanced non-small-cell lung cancer patients and its implications][J]","volume":"99","author":"Xing","year":"2019","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"11","key":"10.1016\/j.biopha.2025.118583_bib33","first-page":"1690","article-title":"Study on the correlation between viral load and activation and exhaustion levels of CD8(+)T cells in HIV\/AIDS patients][J]","volume":"58","author":"Zhan","year":"2024","journal-title":"Zhonghua Yu Fang. Yi Xue Za Zhi"},{"issue":"7","key":"10.1016\/j.biopha.2025.118583_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/v13071234","article-title":"Oropharyngeal squamous cell carcinoma treatment in the era of immune checkpoint Inhibitors[J]","volume":"13","author":"Stern","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.biopha.2025.118583_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1047610","article-title":"PD-1\/LAG-3 bispecific antibody potentiates t cell activation and increases antitumor efficacy[J]","volume":"13","author":"Shi","year":"2022","journal-title":"Front Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118583_bib36","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41587-021-00850-6","article-title":"Bispecific antibodies poised to deliver wave of cancer therapies[J]","volume":"39","author":"Sheridan","year":"2021","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118583_bib37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12943-024-01956-6","article-title":"Efficacy and safety of bispecific antibodies vs. Immune checkpoint blockade combination therapy in cancer: a real-world comparison[J]","volume":"23","author":"Cheng","year":"2024","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2025.118583_bib38","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2124666","article-title":"Immune targeting of three independent suppressive pathways (TIGIT, PD-L1, TGF\u03b2) provides significant antitumor efficacy in immune checkpoint resistant models[J]","volume":"11","author":"Franks","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.biopha.2025.118583_bib39","doi-asserted-by":"crossref","unstructured":"Lipson, E.J.; Tawbi, H.A.-H.; Schadendorf, D.; Ascierto, P.A.; Matamala, L.; Guti\u00e9rrez, E.C.; Rutkowski, P.; Gogas, H.; Lao, C.D.; Janoski de Menezes, J.; Dalle, S.; Arance, A.M.; Grob, J.-J.; Srivastava, S.; Abaskharoun, M.; Simonsen, K.L.; Li, B.; Long, G.V.; Hodi, F.S. Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047)[J]. Journal of Clinical Oncology, 39 (15_suppl):9503-9503.","DOI":"10.1200\/JCO.2021.39.15_suppl.9503"},{"issue":"5","key":"10.1016\/j.biopha.2025.118583_bib40","doi-asserted-by":"crossref","first-page":"487","DOI":"10.4161\/mabs.3.5.16326","article-title":"Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design[J]","volume":"3","author":"Digiammarino","year":"2011","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.biopha.2025.118583_bib41","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s00430-024-00809-9","article-title":"Engineered bispecific antibodies with enhanced breadth and potency against SARS-CoV-2 variants and SARS-related coronaviruses[J]","volume":"213","author":"Chang","year":"2024","journal-title":"Med Microbiol Immunol."},{"issue":"20","key":"10.1016\/j.biopha.2025.118583_bib42","doi-asserted-by":"crossref","first-page":"8121","DOI":"10.1021\/acs.analchem.3c01246","article-title":"Electrochemiluminescence biosensor for Estrogen-Related receptor alpha (ERR\u03b1) based on Target-Induced change of the steric hindrance effect of an Antibody-Modified Electrode[J]","volume":"95","author":"Huang","year":"2023","journal-title":"Anal. Chem."},{"issue":"2, Part A","key":"10.1016\/j.biopha.2025.118583_bib43","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molimm.2015.01.003","article-title":"Alternative molecular formats and therapeutic applications for bispecific antibodies[J]","volume":"67","author":"Spiess","year":"2015","journal-title":"Mol. Immunol."},{"issue":"8","key":"10.1016\/j.biopha.2025.118583_bib44","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.chembiol.2024.07.004","article-title":"Therapeutic potential of cis-targeting bispecific antibodies[J]","volume":"31","author":"Oslund","year":"2024","journal-title":"Cell Chem. Biol."},{"issue":"9","key":"10.1016\/j.biopha.2025.118583_bib45","doi-asserted-by":"crossref","first-page":"6591","DOI":"10.1074\/jbc.M009483200","article-title":"High resolution mapping of the binding site on human IgG1 for fc gamma RI, fc gamma RII, fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the fc gamma R[J","volume":"276","author":"Shields","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.biopha.2025.118583_bib46","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1158\/2326-6066.CIR-19-0121","article-title":"Silencing fc domains in t cell-Engaging bispecific antibodies improves T-cell trafficking and antitumor Potency[J]","volume":"7","author":"Wang","year":"2019","journal-title":"Cancer Immunol. Res"},{"issue":"7","key":"10.1016\/j.biopha.2025.118583_bib47","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.drudis.2015.02.008","article-title":"Bispecific antibodies[J]","volume":"20","author":"Kontermann","year":"2015","journal-title":"Drug Discov. Today"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225007772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225007772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:42:02Z","timestamp":1775781722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225007772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":47,"alternative-id":["S0753332225007772"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118583","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative evaluation of bispecific antibody formats targeting PD-1 and LAG-3 for dual checkpoint blockade in cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118583","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118583"}}